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Objective: Alterations in plasma adipokines and/or inflammatory parameters in Type 2 DM remain vague as to
whether they are due to obesity and/or directly associated with the diabetic state. Our objective was to compare
plasma adiponectin, leptin, leptin/adiponectin ratio (LAR) and hs-CRP in obese non-diabetic subjects and non-obese
Type 2 DM patients, as well as determining the association of these adipokines with MetS and diabetes-related
quantitative traits.
Methods: In this study, 92 Yemeni male volunteers aged 25–60 years old were enrolled, 31 of whom were healthy
subjects with BMI < 25 kg/m2 served as control; 30 non-diabetic obese subjects BMI≥ 30 kg/m2 and FBG < 6.1 mmol/l;
and 31 non-obese Type 2 DM with FBG > 7 mmol/l and BMI < 25 kg/m2.
Results: Adiponectin was lower in obese subjects, with no differences between non-obese Type 2 DM patients and
controls. In contrast, leptin, LAR and hs-CRP were higher in both obese subjects and non-obese Type 2 DM patients.
Linear regression analysis showed adiponectin to be associated negatively with BMI, waist circumference, insulin,
HOMA-β and HOMA-IR; whereas leptin, LAR and hs-CRP were associated positively with BMI, waist circumference, TG,
FBG, insulin, HOMA-β and HOMA-IR. Moreover, adiponectin negatively correlated with leptin, LAR and hs-CRP; whereas
leptin and LAR positively correlated with hs-CRP and with each other.
Conclusion: Plasma adiponectin is not affected by diabetes per se, suggesting that its alterations in Type 2 DM may be
due to obesity and may be an important link between adiposity, IR and Type 2 DM.
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Type 2 DM is a heterogeneous disorder characterized by
two interrelated metabolic defects: insulin resistance (IR)
coupled with impaired β-cell function [1,2]. In individ-
uals with impaired glucose tolerance (IGT), numerous
genetic, host-related, and environmental factors contrib-
ute to the progression of IR to Type 2 DM. Obesity, and
especially visceral adipose tissue accumulation, increases
the risk of developing Type 2 DM [3]. The greater risk
of Type 2 DM in the obese can partly be explained
by changes in adipose tissue function [4,5]. In the last* Correspondence: malhabori@hotmail.com
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article, unless otherwise stated.decade, a hypothesis was proposed to associate the
pathogenesis of Type 2 DM with a state of subclinical
chronic inflammation [6,7]. Epidemiological studies have
demonstrated an increase in plasma levels of inflam-
matory markers such as C-reactive protein (CRP),
interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α)
in patients with metabolic syndrome (MetS) and also in
those with clinically overt Type 2 DM [8]. Chronically ele-
vated levels of these biomarkers promote IR in skeletal
muscle and endothelial dysfunction [9] as well as in adi-
pose and other tissues, thereby increasing the risk for
Type 2 DM [10].
Adiponectin is almost exclusively secreted by adipo-
cytes and appears to acts as a hormone with anti-
inflammatory and insulin-sensitizing properties in vitro
and in animal models and may also promote β-celltral Ltd. This is an Open Access article distributed under the terms of the
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unique among adipokines because its systemic levels
decrease in obesity, whereas most other adipokines
(in particular the pro-inflammatory adipokines) are
released in larger amounts with cell size [12,13]. Adipo-
nectin levels are decreased in cardiovascular disease
and several metabolic disorders including obesity, in-
flammatory states, IR, and Type 2 DM [14,15]. Several
clinical studies have demonstrated hypoadiponectine-
mia correlates with the development of IR and Type 2
DM [16-19]. The majority of these studies show the
adiponectin level in Type 2 DM to be often reduced,
even in the relative early stage of this condition, such
as at time of diagnosis [20,21]. A range of prospective
studies demonstrated that high levels of circulating
adiponectin are associated with low risk of Type 2
DM even after adjustment for multiple factors that
could confound this relationship [22-25].
Leptin is a peptide hormone mainly secreted by white
adipose tissue [26]. Its expression and release are in-
creased in large adipocytes even after normalization for fat
cell volume so that its regulation shows similarities to
the regulation of pro-inflammatory immune-mediators
in adipocytes [13]. It acts on the hypothalamus, leading
to decreased appetite and increased energy expenditure,
thereby regulating body weight [27]. Furthermore, lep-
tin has a number of other activities, including regula-
tion of endocrine function, reproduction and immunity
[26,28]. In humans, obesity is associated with high cir-
culating leptin levels probably reflecting a state of lep-
tin resistance, i.e. impaired leptin signalling and action.
This state could interfere with the physiological rela-
tionship between leptin and β-cell function and promote
the development of IR and Type 2 DM [29]. Previous epi-
demiological studies investigating the association between
circulating leptin levels and incident of Type 2 DM yielded
discrepant results [16,30].
It remains unclear whether the observed alterations in
plasma adipokines and/or inflammatory parameters in
Type 2 DM are due to excess adipose tissue mass and/or
directly associated with the diabetic state [31,32]. We
hypothesize that altered plasma adipokine and/or in-
flammatory factor levels are related to the obese state
and are not prevalent in non-obese Type 2 DM. The
present study compares plasma adipokines and inflam-
matory markers between obese non-diabetic individuals
and non-obese Type 2 DM patients versus non-obese,
normoglycemic controls; as well as evaluating the associ-
ation of adipokines and inflammatory markers with
metabolic syndrome and diabetes-related quantitative
traits. We also examined the Leptin/Adiponectin ra-
tio (LAR) in view of previous reports suggesting that
LAR being a better indicator of IR than the single
adipokines [33].Research design and methods
Study subjects
For this study, a total of 92 Yemeni men subjects aged
25–60 years were recruited from Al-Thwara Hospital,
Sana’a. Thirty one were healthy non-obese, normogly-
caemic subjects with a BMI < 25 kg/m2 served as controls;
30 obese non-diabetic subjects with BMI ≥ 30 kg/m2 and
FBG < 6.1 mmol/L; and 31 non-obese Type 2 DM patients
with blood glucose > 7 mmol/l and BMI < 25 kg/m2. Obese
Type 2 DM patients were excluded in order to exam-
ine the role of diabetes per se. In general, subjects
with acute or chronic infections, severe medical conditions
(malignancy, renal failure, liver cirrhosis, connective tissue
disease, and chronic congestive heart failure) were ex-
cluded from the study. The study protocol was approved
by the institutional review board (IRB) of the Faculty
of Medicine and Health Sciences, Sana’a University.
Informed consent was obtained from all individuals after
explaining the purpose and nature of the study.
Blood pressure (BP) measurements were taken from
each patient’s right arm in the seated position by using
an Omron IntelliSense Automatic Blood Pressure Monitor
after 10 min of rest in a quiet room. Two to three
successive BP readings were obtained at 5 minutes in-
tervals and averaged. Body weight and height were
measured without shoes in the morning, and BMI was
computed as weight in kilograms (kg) divided by height
in meters squared (m2). Waist circumference was mea-
sured midway between the lower rib margin and the su-
perior iliac spine at the end of gentle expiration in a
standing position. Fasting venous blood (6 ml) was col-
lected from each subject after 12 hours fast and imme-
diately taken into 2 labelled test tubes, sodium fluoride
(for glucose measurement) and plain tubes for other
biochemical investigations. The plain tubes were centri-
fuged for 15 minutes at 2500-3000 × g within 30 minutes
of blood collection and the serum from each sample
was separated into four micro tubes and immediately
kept at −20°C until analysis. Plasma glucose was deter-
mined immediately after centrifugation.
Biochemical analyses
Serum triglyceride (TG), HDL-cholesterol (HDL-c), and
plasma glucose (FPG) were manually measured by their
respective kits (Human Company, Germany). Insulin
was measured by Electrochemiluminescence immuno-
assay (ECL) on Elecsys autoanalyzer (Roche Diagnostics,
Germany). Insulin resistance and Insulin sensitivity (IS)
were calculated using the Homeostasis Model Assessment
(HOMA 2) Calculator v2.2 which is available from Oxford
Centre for Diabetes, Endocrinology and Metabolism.
ELISA kits were used to measure serum adiponectin
(R&D Systems, USA), serum leptin and hs-CRP (DRG
Diagnostics, Germany).
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The results were analyzed by the Social Package of
Statistical Science (SPSS) software version 11.5 (SPSS
Inc., Chicago, IL, USA). Age, BMI, waist circumference,
systolic blood pressure (SBP), diastolic blood pressure
(DBP), TG, HDL-c, FBG, insulin, IS, HOMA-IR, adipo-
nectin, leptin, LAR and hs-CRP were log transformed
because they were not normally distributed. These
parameters means and 95% confidence intervals were
transformed back and reported as geometric means.
ANOVA test was used to describe the mean differences
among groups of study. General linear model, univariate
analyses (ANCOVA) adjusted for age was used to assess
the differences of adiponectin, leptin, LAR and hs-CRP
between obese non-diabetic, non-obese Type 2 DM and
normal subjects. The association of adiponectin, leptin,
LAR and hs-CRP with metabolic syndrome and diabetes-
related qualitative traits: BMI, waist circumference,
SBP, DBP, TG, HDL-c, FBG, insulin, IS, HOMA-β and
HOMA-IR (dependent variables) were analyzed by hier-
archical linear regression adjusted for age in a combined
group: normal and obese non-diabetic subjects. The
interrelationship between adiponectin, leptin, LAR and
hs-CRP in non-diabetic subjects were evaluated by linear
regression controlled for age.
Results
The demographic and biochemical parameters of the
subjects are shown in Table 1. The adiponectin, leptin,
LAR and hs-CRP assessed by general linear model
(univariate) are shown in Table 2. Serum levels of adipo-
nectin were significantly lower in obese non-diabetic sub-
jects compared to control and non-obese Type 2 DM
subjects (p = 0.002, 0.006 respectively), with no differ-
ences in adiponectin levels between non-obese Type 2
DM subjects and controls. In contrast, serum leptin
levels and LAR were higher in both obese non-diabeic
subjects (p = 3.6 × 10−30, 1.1 × 10−26) and non-obese Type
2 DM (p = 2.8 × 10−19, 2.9 × 10−12, respectively) as com-
pared to control subjects. In addition, serum leptin levels
and LAR in obese subjects were higher with respect to
non-obese Type 2 DM subjects (p = 2.7 × 10−4, 1.4 × 10−7,
respectively). Similarly, serum hs-CRP levels were higher
in both obese subjects and non-obese Type 2 DM pa-
tients as compared to control subjects (p = 4.3 × 10−6,
8.2 × 10−10, respectively). Unlike that of leptin and LAR,
serum hs-CRP levels were higher in non-obese Type 2
DM than those in obese subjects (p = 0.019).
The association of the inflammatory related variables
(adiponectin, leptin, LAR and hs-CRP) with metabolic
syndrome and diabetes-related qualitative traits was eval-
uated in the combined group; normal and obese non-
diabetic subjects (Table 3). Serum levels of adiponectin
associated with increased HDL-c and IS, and decreasedBMI, waist circumference, insulin, HOMA-β and HOMA-
IR. In contrast, serum leptin levels and LAR associated
with decreased IS, and increased BMI, waist circumference,
DBP, SBP, TG, FBG, insulin, HOMA-β and HOMA-IR. On
the other hand, hs-CRP associated with decreased HDL-c
and IS, and increased BMI, waist circumference, DBP, SBP,
TG, FBG, insulin, HOMA-β, and HOMA-IR.
The interrelationship between adiponectin, leptin, LAR
and hs-CRP parameters was further assessed in the com-
bined group; normal and obese non-diabetic subjects as
shown in Table 4. Serum adiponectin levels negatively
correlated with leptin, LAR and hs-CRP (r2 = −0.216,
p = 0.002; r2 = −0.268, p = 0.0001; r2 = −0.098, p = 0.006). In
contrast, serum leptin levels and LAR positively correlated
with hs-CRP (r2 = −0.528, p = 5.8 × 10−11; r2 = −0.527, p =
6.7 × 10−11 respectively), and with each other (r2 = −0.668,
p = 1.4 × 10−14).
Discussion
The results presented in our study shows plasma adipo-
nectin not to be affected by diabetes per se whereby adi-
ponectin was significantly lower in obese individuals as
compared to both control and non-obese Type 2 DM,
with no difference in adiponectin between non-obese
Type 2 DM and control group; thus suggesting that the
often reported alterations in plasma adiponectins in
Type 2 DM [32,34,35] may be due to excess adipose tis-
sue mass/ obesity. In accordance with our results, a re-
cent finding suggested that adiponectin levels in patients
with Type 2 DM seem to be more associated with obes-
ity and less with diabetes [36]. In general most of the
Type 2 DM patients included in those studies were
obese. To differentiate between the impact of obesity
and type 2 diabetes on the altered plasma adipokine
and/or inflammatory profiles, a recent study compares
basal plasma adipokines and inflammatory markers be-
tween obese and non-obese type 2 diabetes patients
versus non-obese, normoglycemic controls and conclude
that the observed alterations in these parameters in
obese type 2 diabetes patients as opposed to non-obese
Type 2 DM are attributed to the greater adipose tissue
mass, and not necessarily to the presence of the type 2
diabetic state [37]. Taking into account the ethnical vari-
ation our study was designed to assess the association of
these adipokines in Yemeni Type 2 DM patients as well
as highlighting the impact of diabetes per se.
Our results also show adiponectin to be associated
with metabolic syndrome and diabetes-related qualita-
tive traits, whereby adiponectin was associated with
increased HDL-c and IS; and decreased BMI, waist cir-
cumference, insulin, HOMA-IR and HOMA-β; which is
in line with previous studies [38-40]. Many studies sug-
gest that adiponectin is an important regulator of insulin
sensitivity and glucose homeostasis, with several reports
Table 2 Comparison of adiponectin, leptin, leptin/
adiponectin ratio (LAR) and hs-CRP between normal,
non-diabetic obese and non-obese type 2 DM groups
Parameters Normal(n = 31)
Non-diabetic
obese (n = 30)
Non-obese
T2DM (n = 31)
Adiponectin (IU/ml) 25 (20.6-30.2) 16.3 (13.3-19.9) 25.8 (20.6-32.2)
p-value a0.002 a0.83, b0.006
Leptin (ng/ml) 14 (12–17) 141 (116–172) 78 (63–96)




0.59 (0.36-0.85) 8.21 (6.78-9.90) 3.31 (2.61-4.15)
p-value a1.1 × 10−26 a2.9 × 10−12,
b1.4 × 10−7
hs-CRP (U/ml) 15.2 (14.7-15.7) 17.0 (16.5-17.7) 18.2 (17.6-19.0)
p-value a4.3 × 10−6 a8.2 × 10−10,
b0.019
Results presented as geometric mean and 95% confidence interval of mean
adjusted for age; avs. normal group, bvs. non-diabetic obese group evaluated
by univariate (General Linear Model).
Table 1 Demographic and biochemical parameters among normal, non-diabetic obese and non-obese type 2 diabetes
mellitus groups
Parameters Normal (n = 31) Non-diabetic obese (n = 30) Non-obese T2DM (n = 31)
Age (years) 31.3 (27.8-35.2) 28.4 (26.6-32.4) 45.2 (39.8-51.3)
p-value a0.44 a4.5 × 10−5, b4.0 × 10−5
BMI (kg/m2) 20.6 (19.7-21.5) 34.0 (32.5-35.5) 22.3 (21.1-23.7)
p-value a5.1 × 10−9 a0.53, b5.1 × 10−9
Waist circumference (cm) 75.1 (72.7-77.6) 90.2 (88.0-92.5) 71.3 (69.2-73.5)
p-value a5.1 × 10−9 a0.037, b5.1 × 10−9
DBP (mmHg) 75.5 (72.5-78.7) 85.2 (82.8-87.6) 83.5 (79.8-87.3)
p-value a4.9 × 10−5 a0.00096, b0.74
SBP (mmHg) 113 (109–117) 126 (123–130) 123 (116–130)
p-value a2.3 × 10−4 a0.009, b0.56
Triglyceride (mmol/l) 1.5 (1.2-1.8) 2.1 (2.0-2.2) 2.0 (1.8-2.2)
p-value a0.0009 a0.005, b0.88
HDL-c (mmol/l) 0.9 (0.8-1.0) 0.8 (0.7-0.9) 0.7 (0.6- 0.8)
p-value a0.23 a0.01, b0.34
FBG (mmol/l) 5.4 (5.1-5.8) 5.7 (5.5-6.0) 9.7 (8.3-11.4)
p-value a0.66 a5.1 × 10−9, b5.2 × 10−9
Insulin (pmol/l) 44.5 (37.2-53.2) 130 (112–151) 70.1 (54.3-90.5)
p-value a5.1 × 10−9 a0.004, 5.9 × 10−5
HOMA-β 73.2 (62.3-85.9) 135 (119–154) 33.7 (23.0-49.2)
p-value a0.0007, a3.2 × 10−5, b5.1 × 10−9
Insulin Sensitivity (%) 118 (99–142) 40.8 (35.2- 47.3) 62.4 (49.0-79.3)
p-value a5.1 × 10−9 a1.6 × 10−5, 0.006
HOMA-IR 0.9 (0.7-1.1) 2.5 (2.2-2.9) 1.7 (1.3-2.2)
p-value a5.1 × 10−9 a4.9 × 10−5, 0.005
Result presented as geometric mean and 95% confidence interval of mean; avs. normal group; bvs. non-diabetic obese group evaluated by ANOVA.
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sistance and plasma adiponectin levels [19,23,41]. The
evidence that insulin may have direct effect on adiponec-
tin gene expression and adiponectin concentrations
in vitro [42] may infer that the higher levels of insulin in
insulin-resistant subjects may down-regulate levels of
adiponectin [43]. However, the inverse association be-
tween adiponectin and IR in our results and others
[39,40] may possibly be mediated not only by insulin but
also by inflammatory cytokines [44]. Moreover, the posi-
tive association between adiponectin and HDL-c is in
support of earlier studies in the general population [38]
and obese subjects [45], suggesting that adiponectin
plays a role in HDL metabolism.
Unlike adiponectin, serum leptin levels and LAR were
higher in both obese individuals and non-obese Type 2
DM patients with respect to the control group. In
addition, serum leptin levels and LAR in obese subjects
were higher compared to non-obese Type 2 DM. Our
Table 3 Association of adiponectin, leptin, leptin/adiponectin ratio (LAR) and hs-CRP with metabolic syndrome and
diabetic parameters among non-diabetic subjects (n = 61)
Metabolic syndrome parameters Adiponectin (IU/ml) Leptin (ng/ml) Leptin/Adiponectin Ratio hs-CRP (U/ml)
BMI (kg/m2) −0.213 (0.0007) 0.049 (1.1 × 10−11) 0.208 (3.2 × 10−9) 3.256 (2.2 × 10−10)
Waist circumference (cm) −0.368 (9.5 × 10−5) 0.070 (1.6 × 10−9) 0.706 (8.2 × 10−7) 5.302 (2.1 × 10−10)
DBP (mmHg) −0.032 (0.789) 0.044 (0.001) 0.481 (0.003) 2.955 (0.002)
SBP (mmHg) 0.009 (0.916) 0.032 (0.001) 0.309 (0.01) 1.685 (0.015)
Triglyceride (mmol/l) −0.004 (0.208) 0.002 (0.0001) 0.014 (0.003) 0.127 (2.8 × 10−6)
HDL-c (mmol/l) 0.005 (0.034) −0.0003(0.203) −0.006 (0.061) −0.035 (0.050)
LDL-c (mmol/l) - 0.011 (0.157) 0.003 (0.0016) 0.024 (0.032) 0.117 (0.074)
FBG (mmol/l) - 0.005 (0.468) 0.003 (0.003) 0.023 (0.02) 0.143 (0.016)
Insulin (pmol/l) −1.163 (0.018) 0.285 (1.1 × 10−6) 0.342 (5.3 × 10−6) 22.91 (1.6 × 10−8)
HOMA-β −1.152 (0.006) 0.132 (0.01) 0.143 (0.002) 14.44 (6.3 × 10−5)
Insulin Sensitivity (%) 1.583 (0.001) −0.279 (2.7 × 10−5) −0.248 (0.0001) −20.3 ((4.3 × 10−6)
HOMA-IR −0.021 (0.021) 0.006(6.3 × 10−7) 0.344 (4.6 × 10−6) 0.436 (1.3 × 10−8)
Results presented represent b values (p values) assessed by linear regression adjusted for age; (b) coefficient for the relationship between the dependent variables
(adiponectin, leptin, LAR and hs-CRP) and the independent variables (metabolic syndrome and diabetic parameters).
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culating leptin levels to be higher in obese individuals
and patients with MetS [40,46]. Earlier reports showed
circulating leptin concentrations to be elevated in obese
subjects in proportion to the degree of adiposity [46]
and positively correlated with body fat mass, despite
anti-obesity actions of leptin [47]. In vitro studies also
indicated that leptin secretion was significantly greater
in enlarged adipocytes [13].
Our results show that adiponectin levels and that of
leptin and LAR exhibit opposing and variable correla-
tions with obesity, IR and the components of the meta-
bolic syndrome; whereby leptin levels and LAR were
associated with decreased IS and increased BMI, waist
circumference, SBP, DBP, TG, FBG, insulin, HOMA-IR
and HOMA-β. These findings are in agreement with
previous studies [39,40,48]. High leptin levels generally
associated with high insulin levels could be partially
explained by a state of leptin resistance such that chron-
ically elevated leptin levels in obesity may result in
decreased responsiveness of the receptor system in pan-
creatic β cells, leading to increased insulin secretion.
The resulting hyperinsulinaemia in turn could exacer-
bate obesity and further increase leptin levels, resulting
in a positive feedback loop that could promote theTable 4 Correlation between adiponectin, leptin, leptin/Adipo
subjects (n = 61)
Parameters Adiponectin (IU/ml) Leptin (ng
Adiponectin (IU/ml) 1 −0.216 (0.
Leptin 1
Leptin/Adiponectin
Result presented as adjusted r2 (P-value) assessed by Linear regression, adjusted fodevelopment of diabetes [24,29]. Accordingly, our results
show a close relationship between insulin and leptin
levels in non-diabetic obese subjects.
Our results also show an inverse association between
leptin and adiponectin which highlights the recent find-
ings that indicated that the two adipokines interact with
each other in the modulation of Type 2 DM risk [24].
Perhaps this association could be secondary to the in-
verse relation of these adipokines with fat mass; direct
relation of leptin; and inverse relation of adiponectin. In
obesity where plasma adipokine levels are reduced, this
can be used as a marker of insulin resistance and predict
the development of Type 2 DM and atherosclerosis [41].
The observed increase in LAR in both obese individuals
and non-obese Type 2 DM as compared to the increase
in HOMA-IR may suggest that LAR could be a useful
index for insulin resistance. This is in line with recent
suggestion that LAR could serve as a useful index for in-
sulin resistance in clinical practice and a good indicator
for assessing the effectiveness of anti-diabetic therapy
[33] as well as a potential atherogenic index in obese
Type 2 DM patients [49].
Since chronic inflammation is likely to play a role
in the pathogenesis of Type 2 DM, we also examined
the association between adipocytokines and hs-CRP, annectin ratio and hs-CRP parameters among non-diabetic
/ml) Leptin/Adiponectin ratio hs-CRP (U/ml)
002) −0.268 (0.0001) −0.098 (0.006)
0.668 (1.4 × 10−14) 0.528 (5.8 × 10−11)
1 0.527 (6.7 × 10−11)
r age.
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cardiovascular events; and found that adiponectin was
inversely correlated with hs-CRP levels, which is in
agreement with earlier studies [50] inferring that adipo-
nectin may be an important link between adiposity, in-
flammation and Type 2 DM [41]. Therefore, adiponectin
may directly or indirectly affect CRP levels through
modulating inflammatory cascades [35]. Moreover, we
found a positive association between serum leptin levels
and hs-CRP, which can be explained in part by the fact
that adipocytes by serving as a common source for
both leptin and inflammatory cytokines contribute to
CRP synthesis. Leptin may directly induce production
of IL-6, resulting in up-regulation of hepatic CRP pro-
duction [26].
Serum hs-CRP levels were higher in both obese indi-
viduals and non-obese Type 2 DM compared to control
group. Unlike that of leptin and LAR, serum hs-CRP
levels were higher in non-obese Type 2 DM than that in
obese subject, which is concordant with several cross-
sectional studies showing an increase of CRP levels
in patients with diabetes [32,35,51,52]. Epidemiological
studies have demonstrated an increase in plasma levels
of inflammatory markers such as CRP, IL-6 and TNF-α
in patients with MetS and also in those with clinically
overt Type 2 DM [8]. C-reactive protein also appears to
progressively increase when glucose metabolism deterio-
rates, as evident in subjects with IFG and Type 2 DM
[34,53]. The significant increment of serum hs-CRP
levels in our non-obese Type 2 DM, and the positive
correlation between hs-CRP and HOMA-IR suggest that
chronic inflammation may play a role in the develop-
ment of insulin resistance and Type 2DM. The patho-
physiological mechanisms linking obesity to elevated
levels of CRP are well recognized [4]. In a recent system-
atic review and meta-analysis, obesity was strongly asso-
ciated with elevated levels of CRP in all populations
observed [54]. The ongoing debate regarding the associ-
ation among chronic inflammatory states; insulin resist-
ance and obesity provide a conflicting hypothesis that
chronic inflammatory state originates from obesity and
drives the insulin resistant condition. Moreover, hs-CRP
in non-diabetic subjects was associated with decreased
HDL-c and IS and increased BMI, waist circumference,
SBP, DBP, TG, FBG, insulin, HOMA-IR and HOMA-β,
which is in line with previous studies demonstrating a
significant correlation between CRP levels and features
of the MetS; including adiposity, hyperinsulinemia and
IR [55,56]. The observed strong association of fasting
insulin with CRP concentration has previously been
demonstrated [57].
There were some limitations in this study; first, the
study is hospital based and all subjects were male there-
fore the findings may not generally be applicable to theoverall population. Second, the sample size was small,
limiting its statistical power for detecting associations.
Third, the β–cell function was evaluated using the
homeostasis model (HOMA- β and HOMA-IR) as there
is no “gold standard” method to evaluate β-cell function/
mass in vivo. Nevertheless, this study represents a simul-
taneous investigation of relationships between serum
adipokine profile and inflammatory markers in Yemeni
non-obese Type 2 DM patients.
In conclusion, plasma adiponectin was not affected by
diabetes per se, suggesting that the often reported alter-
ations in plasma adiponectins in Type 2 DM may be due
to excess adipose tissue mass/ obesity. Adiponectin and
leptin exhibited opposing and variable correlations with
obesity, IR and the components of the metabolic syn-
drome. In addition, LAR was strongly correlated with
the HOMA-IR supporting findings that LAR could be a
potential marker of IR. The inverse association between
adiponectin and hs-CRP infers that adiponectin may be
an important link between adiposity, inflammation and
Type 2 DM. Moreover, the significant increment of
hs-CRP in non-obese Type 2 DM, and its positive
correlation with HOMA-IR suggest that chronic inflamma-
tion may play a role in the development of insulin resist-
ance and Type 2DM.
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